English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Results Assessment of the relative binding revealed that 86% (69/80) and 99% (79/80) of the plasma were able to reach an IC50 binding titer with V3B peptide and V3C peptides respectively; with substantially low antibody titers that bind to V3B than V3C (mean IC50, V3B=2736 versus V3C=12612) (p<0.0001). The finding suggests that although majority of the antibodies were subtype specific, a good proportion of cross reactive anti-V3 antibodies also exist in these plasma (mean=23% range=0.11-97%). We observed a positive correlation between percent cross reactive anti-V3 antibodies and days from first diagnosis (p=0.008) while no such association was found with other clinical and immunological parameters like plasma viral load (p=0.24), CD4 count (p=0.34) and total plasma IgG levels (p=0.45).

Cross clade reactive plasma anti-V3 antibodies in human immunodeficiency virus type-1 infected individuals develop with time